Arnold Library

Hormone therapy and ovarian cancer: incidence and survival.

Wernli, Karen J and Newcomb, Polly A and Hampton, John M and Trentham-Dietz, Amy and Egan, Kathleen M (2008) Hormone therapy and ovarian cancer: incidence and survival. Cancer causes & control : CCC, 19 (6). pp. 605-613. ISSN 0957-5243

[thumbnail of Complete manuscript]
Preview
Text (Complete manuscript)
WernliKFullManuscript032509.pdf
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (163kB) | Preview
Article URL: http://www.springerlink.com/content/f177210h718654...

Abstract

OBJECTIVE: We conducted a population-based case-control study to investigate the association between hormone therapy (HT) and ovarian cancer incidence, and followed all these cancer cases to determine the association of HT use with ovarian cancer mortality. METHODS: Seven hundred fifty-one incident cases of invasive epithelial ovarian cancer aged 40-79 years were diagnosed in Massachusetts and Wisconsin between 1993-1995 and 1998-2001 and matched to similarly aged controls (n = 5,808). Study subjects were interviewed by telephone, which ascertained information on HT use and specific preparation, estrogen alone (E-alone) or estrogen plus progestin (EP). Ovarian cancer cases were followed-up for mortality through December 2005. Multivariate logistic regression was used to estimate odds ratios and 95% confidence intervals (CI) for ovarian cancer incidence, and Cox proportional hazards modeling was used to estimate hazard ratios and corresponding confidence intervals for ovarian cancer mortality. RESULTS: Ever use of HT was significantly associated with an increased risk of ovarian cancer (odds ratio 1.57, 95% CI 1.31-1.87). The excess risk was confined to women who used E-alone preparations (OR 2.33, 95% CI 1.85-2.95). No significant associations were detected between pre-diagnosis HT use and ovarian cancer survival. CONCLUSIONS: Hormone therapy increases risk of ovarian cancer among E-alone users, but there is no substantial impact on survival after diagnosis.

Item Type: Article or Abstract
Additional Information: This article is available to subscribers only via the URL above.
DOI: 10.1007/s10552-008-9125-x
PubMed ID: 18264784
NIHMSID: NIHMS105378
PMCID: PMC2729759
Grant Numbers: R01 CA047147-17, R01 CA047305-12
Keywords or MeSH Headings: Adult; Aged; Case-Control Studies; Female; Hormone Replacement Therapy/adverse effects/statistics & numerical data; Humans; Incidence; Kaplan-Meiers Estimate; Massachusetts/epidemiology; Middle Aged; Odds Ratio; Ovarian Neoplasms/etiology/mortality; Survival Analysis; Wisconsin/epidemiology;
Subjects: Diseases > Solid tumors > Ovarian cancer
Molecules > Hormones
Research Methodologies > Epidemiology
Depositing User: Library Staff
Date Deposited: 25 Mar 2009 21:29
Last Modified: 14 Feb 2012 14:42
URI: http://authors.fhcrc.org/id/eprint/264

Repository Administrators Only

View Item View Item